Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors

被引：72

作者：

Bamborough, Paul ^{[1
]}

Chung, Chun-wa ^{[1
]}

Furze, Rebecca C. ^{[2
]}

Grandi, Paola ^{[4
]}

Michon, Anne-Marie ^{[4
]}

Sheppard, Robert J. ^{[2
]}

Barnett, Heather ^{[3
]}

Diallo, Hawa ^{[2
]}

Dixon, David P. ^{[1
]}

Douault, Clement ^{[2
]}

Jones, Emma J. ^{[1
]}

Karamshi, Bhumika ^{[1
]}

Mitchell, Darren J. ^{[2
]}

Prinjha, Rab K. ^{[2
]}

Rau, Christina ^{[4
]}

Watson, Robert J. ^{[2
]}

Wemer, Thilo ^{[4
]}

Demont, Emmanuel H. ^{[2
]}

机构：

[1] GlaxoSmithKline Med Res Ctr, Mol Discovery Res, Stevenage SG1 2NY, Herts, England

[2] GlaxoSmithKline Med Res Ctr, Epinova Discovery Performance Unit, Stevenage SG1 2NY, Herts, England

[3] GlaxoSmithKline Med Res Ctr, Flexible Discovery Unit, Stevenage SG1 2NY, Herts, England

[4] GlaxoSmithKline, Mol Discovery Res, Cellzome GmbH, D-69117 Heidelberg, Germany

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 58卷 / 15期

关键词：

DISCOVERY;

D O I：

10.1021/acs.jmedchem.5b00773

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

ATAD2 is a bromodomain-containing protein whose overexpression is linked to poor outcomes in a number of different cancer types. To date, no potent and selective inhibitors of the bromodomain have been reported. This article describes the structure-based optimization of a series of naphth-yridones from micromolar leads with no selectivity over the BET bromodomains to inhibitors with sub-100 nM ATAD2 potency and 100-fold BET selectivity.

引用

页码：6151 / 6178

页数：28

共 50 条

[21] Structure-based design and optimization of potent inhibitors of the adenoviral protease
Grosche, Philipp
Sirockin, Finton
Mac Sweeney, Aengus
Ramage, Paul
Erbel, Paul
Melkko, Samu
Bernardi, Anna
Hughes, Nicola
Ellis, David
Combrink, Keith D.
Jarousse, Nadine
Altmann, Eva
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 438 - 443
[22] Structure-based optimization of a potent class of arylamide FMS inhibitors
Meegalla, Sanath K.
Wall, Mark J.
Chen, Jinsheng
Wilson, Kenneth J.
Ballentine, Shelley K.
DesJarlais, Renee L.
Schubert, Carsten
Crysler, Carl S.
Chen, Yanmin
Molloy, Christopher J.
Chaikin, Margery A.
Manthey, Carl L.
Player, Mark R.
Tomczuk, Bruce E.
Illig, Carl R.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (12) : 3632 - 3637
[23] Structure-based optimization of potent PDK1 inhibitors
Angiolini, Mauro
Banfi, Patrizia
Casale, Elena
Casuscelli, Francesco
Fiorelli, Claudio
Saccardo, Maria B.
Silvagni, Marco
Zuccotto, Fabio
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (14) : 4095 - 4099
[24] Disulfide bridge formation contributes to histone ligand recognition by the ATAD2 bromodomain
Evans, Chiara
Gay, Jamie
Eckenroth, Brian E.
Carlson, Samuel
Lloyd, Jonathan T.
Glass, Karen C.
FASEB JOURNAL, 2018, 32 (01):
[25] Hitting a Moving Target: Simulation and Crystallography Study of ATAD2 Bromodomain Blockers
Dolbois, Aymeric
Batiste, Laurent
Wiedmer, Lars
Dong, Jing
Brutsch, Manuela
Huang, Danzhi
Deerain, Nicholas M.
Spiliotopoulos, Dimitrios
Cheng-Sanchez, Ivan
Laul, Eleen
Nevado, Cristina
Sledz, Pawel
Caflisch, Amedeo
ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (08): : 1573 - 1580
[26] Structure-based optimization of potent, aminothiadiazole inhibitors of Akt1
Hegde, Sayee G.
Bahmanyar, Sogole
Harris, Roy
Hilgraf, Robert
Lee, Branden
McCarrick, Meg
McKie, Jeff
Nadolny, Lisa
Perrin-Ninkovic, Sophie
Sapienza, John
Collette, Alice
Cox, Sarah
Gamez, Jim
Hensel, Jennifer
Hua, Helen
Leisten, Jim
Narla, Rama K.
Raymon, Heather K.
Tam Tran
Mortensen, Deborah S.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
[27] Reading the message: A structural and functional comparison of the ATAD2/B bromodomain binding activity
Glass, Karen
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2022, 78 : A100 - A100
[28] Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors
Hu, Jianping
Tian, Chang-Qing
Damaneh, Mohammadali Soleimani
Li, Yanlian
Cao, Danyan
Lv, Kaikai
Yu, Ting
Meng, Tao
Chen, Danqi
Wang, Xin
Chen, Lin
Li, Jian
Song, Shan-Shan
Huan, Xia-Juan
Qin, Lihuai
Shen, Jingkang
Wang, Ying-Qing
Miao, Ze-Hong
Xiong, Bing
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (18) : 8642 - 8663
[29] Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors
Jessop, Theodore C.
Tarver, James E.
Carlsen, Marianne
Xu, Amy
Healy, Jason P.
Heim-Riether, Alexander
Fu, Qinghong
Taylor, Jerry A.
Augeri, David J.
Shen, Min
Stouch, Terry R.
Swanson, Ronald V.
Tari, Leslie W.
Hunter, Michael
Hoffman, Isaac
Keyes, Philip E.
Yu, Xuan-Chuan
Miranda, Maricar
Liu, Qingyun
Swaffield, Jonathan C.
Kimball, S. David
Nouraldeen, Amr
Wilson, Alan G. E.
Foushee, Ann Marie DiGeorge
Jhaver, Kanchan
Finch, Rick
Anderson, Steve
Oravecz, Tamas
Carson, Kenneth G.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (23) : 6784 - 6787
[30] Discovery and structure-based optimization of potent, covalent inhibitors of Taspase1
Neitz, Jeff
Arkin, Michelle
Waterson, Alex
Sambucetti, Lidia
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256

← 1 2 3 4 5 →